Valuation: Seres Therapeutics, Inc.

Market Cap 48.08M 42.27M 39.35M 36.13M 67.85M 4.61B 68.75M 468M 183M 2.28B 180M 177M 7.87B P/E 2026 *
-0.66x
P/E 2027 * -0.76x
Enterprise Value 48.08M 42.27M 39.35M 36.13M 67.85M 4.61B 68.75M 468M 183M 2.28B 180M 177M 7.87B EV / Sales 2026 *
3.74x
EV / Sales 2027 * 134x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-0.20%
1 week-2.15%
Current month-36.63%
1 month-35.82%
3 months-31.70%
6 months-67.62%
Current year-66.40%
1 week 4.9
Extreme 4.9
5.44
1 month 4.9
Extreme 4.9
8.25
Current year 4.9
Extreme 4.9
16.42
1 year 4.9
Extreme 4.9
29.98
3 years 4.9
Extreme 4.9
105.8
5 years 4.9
Extreme 4.9
233.8
10 years 4.9
Extreme 4.9
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
President 51 01/03/2026
Chief Executive Officer 58 31/07/2025
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

Director

6,500 0.0671%
08/07/26 Free

Director

6,500 0.0671%
08/07/26 Free

Director

6,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.15%-62.24%-94.34% 48.08M
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-0.86%-0.56%+4.59%+421.67% 23.18B
+2.76%-0.24%-18.49%-12.44% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.27%+1.06%+26.42%+186.33% 13.92B
Average +0.64%+0.77%+31.87%+151.04% 24.01B
Weighted average by Cap. +0.08%+1.93%+40.00%+139.05%

Financials

2026 *2027 *
Net sales 12.86M 11.3M 10.52M 9.66M 18.15M 1.23B 18.38M 125M 48.85M 609M 48.27M 47.23M 2.1B 358K 315K 293K 269K 505K 34.33M 512K 3.48M 1.36M 16.95M 1.34M 1.31M 58.59M
Net income -70.97M -62.39M -58.08M -53.33M -100M -6.81B -101M -690M -270M -3.36B -266M -261M -11.62B -99.82M -87.75M -81.69M -75.02M -141M -9.57B -143M -971M -379M -4.73B -375M -367M -16.34B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
27/07/26 US$4.980 +0.30% 56,129
24/07/26 US$4.965 -5.07% 84,528
23/07/26 US$5.230 -0.95% 29,816
22/07/26 US$5.280 +0.57% 28,772
21/07/26 US$5.250 +2.74% 26,940
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.965USD
Average target price
17.00USD
Spread / Average Target
+242.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock